Silexion Therapeutics (NASDAQ: SLXN) deepens 2026 losses while advancing SIL204 Phase 2/3 trial
Rhea-AI Filing Summary
Silexion Therapeutics Corp reported larger losses for the three and six months ended June 30, 2026 while advancing its lead RNAi candidate SIL204 into an active Phase 2/3 trial in locally advanced pancreatic cancer. Regulatory approvals in Israel and from Germany’s BfArM enabled trial initiation, with the first site activated at Tel Aviv Sourasky Medical Center in July 2026 and additional Israeli and German sites progressing toward activation. New preclinical immuno-oncology data showed statistically significant effects on MHC-I, FAS (CD95), and HLA-G across four KRAS mutations, supporting future combination with anti-PD-(L)1 checkpoint inhibitors.
R&D expenses rose to $2.2 million in the quarter and $3.6 million year-to-date, driving a net loss of $3.6 million for the quarter and $6.3 million for the six months. Cash and cash equivalents declined to $2.2 million and total assets to $4.2 million, while shareholders’ equity narrowed to $44 thousand. The company executed multiple capital-structure actions, including a 1-for-10 reverse split and a registered public offering with $2.5 million gross proceeds and approximately $2.1 million net proceeds, and highlighted substantial doubt about its ability to continue as a going concern in its financial statements.
Positive
- SIL204 advanced into an active Phase 2/3 trial in locally advanced pancreatic cancer, with regulatory approvals in Israel and Germany and first site initiation at Tel Aviv Sourasky Medical Center.
- New immuno-oncology data for SIL204 showed statistically significant modulation of MHC-I, FAS (CD95), and HLA-G across four KRAS mutations, supporting combination with anti-PD-(L)1 checkpoint inhibitors.
- Capital raised via financing transactions, including an August 13, 2026 registered public offering with approximately $2.5 million gross and $2.1 million net proceeds, to support the Phase 2/3 program and Nasdaq listing compliance.
Negative
- Net loss increased 44.0% year over year for the quarter to $3.6 million, and 50.0% for the six months to $6.3 million, driven by higher R&D and G&A expenses.
- Cash and cash equivalents fell from $5.991 million at December 31, 2025 to $2.229 million at June 30, 2026, significantly reducing the company’s liquidity.
- Shareholders’ equity shrank sharply from $2.603 million to $44 thousand, and the company referenced substantial doubt about its ability to continue as a going concern.
- Operating expenses more than doubled year to date, with R&D up 125.0% and G&A up 21.7%, increasing the cash burn needed to fund development.
Filing Explained
At June 30, 2026, reported liabilities exceeded shareholders’ equity.
This August 14 Form 8-K furnishes second-quarter results and a business update; the June 30 balance sheet, before the August 13 offering, reported liabilities and shareholders’ equity, with liabilities greater than equity.
The August 13 public offering is reported as closed, with approximately
Current liabilities included a related-party promissory note.
For follow-up, the filing points to the June 30 Form 10-Q for the substantial-doubt disclosure in Note 1(g) and the referenced legal proceedings.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Net Loss: $3.6 million
Six-Month 2026 Net Loss: $6.3 million
Q2 2026 R&D Expense: $2.2 million
+5 more
8 metrics
Q2 2026 Net Loss
$3.6 million
Net loss for the three months ended June 30, 2026, up 44.0% from Q2 2025
Six-Month 2026 Net Loss
$6.3 million
Net loss for the six months ended June 30, 2026, up 50.0% year over year
Q2 2026 R&D Expense
$2.2 million
Research and development expenses for the quarter, a 120.0% increase vs. Q2 2025
Six-Month 2026 R&D Expense
$3.6 million
Research and development expenses for the six months, up 125.0% vs. 2025
Cash and Cash Equivalents
$2.229 million
Cash and cash equivalents as of June 30, 2026
Shareholders’ Equity
$44 thousand
Total shareholders’ equity as of June 30, 2026, down from $2.603 million at year-end 2025
Public Offering Proceeds
$2.5 million gross; $2.1 million net
Registered public offering closed August 13, 2026 to support clinical program and listing compliance
Ordinary Shares Outstanding
1,179,844 shares
Ordinary shares issued and outstanding as of June 30, 2026 after 1-for-10 reverse split
Key Terms
Phase 2/3 clinical trial, RNA interference (RNAi), KRAS mutations, anti-PD-(L)1 checkpoint inhibitor therapies, +2 more
6 terms
Phase 2/3 clinical trial medical
"advanced SIL204 into active Phase 2/3 clinical evaluation in locally advanced pancreatic cancer"
A phase 2/3 clinical trial is a single, combined study that first tests whether a treatment works and is safe in a modest number of patients, then expands seamlessly into a larger, confirmatory stage if early results are promising. Think of it like a prototype test that can quickly move into full production without starting over; for investors, it concentrates risk and time, because positive results can speed regulatory approval while negative results can be a major setback.
RNA interference (RNAi) medical
"a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers"
A natural cellular process in which small RNA molecules shut down the production of a specific protein by blocking the instructions that make it, like flipping a precise light switch to silence one appliance without affecting others. For investors, RNA interference is important because it underpins a class of highly targeted therapies and research tools that can create new drugs, shorten development paths, and change the potential market and regulatory risks for companies working on gene-based treatments.
KRAS mutations medical
"observed across four KRAS mutations (G12D, G12V, G12C, and G12R)"
A KRAS mutation is a change in the KRAS gene that makes a cell’s growth-control protein act like a gas pedal stuck down, driving uncontrolled cell division that can cause cancer. For investors, KRAS mutations matter because they determine whether certain drugs or tests will work, influence clinical trial outcomes and regulatory decisions, and shape the commercial size and timing of oncology product opportunities.
anti-PD-(L)1 checkpoint inhibitor therapies medical
"reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitor therapies"
going concern financial
"the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(g)"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Earnings Snapshot
Q2 2026 Net Loss: $3.6 million
Three and six months ended June 30, 2026
Q2 2026 Net Loss
$3.6 million
Increased 44.0% from approximately $2.5 million in Q2 2025
Six-Month 2026 Net Loss
$6.3 million
Increased 50.0% from approximately $4.2 million for the six months ended June 30, 2025
Q2 2026 R&D Expenses
$2.2 million
Increased 120.0% from approximately $1.0 million in Q2 2025
Six-Month 2026 R&D Expenses
$3.6 million
Increased 125.0% from approximately $1.6 million in the prior-year period
Q2 2026 G&A Expenses
$1.5 million
Increased 15.4% from approximately $1.3 million in Q2 2025
Six-Month 2026 G&A Expenses
$2.8 million
Increased 21.7% from approximately $2.3 million in the prior-year period
FAQ
How did Silexion Therapeutics (SLXN) perform financially in Q2 2026?
Silexion reported a Q2 2026 net loss of $3.6 million, up from $2.5 million a year earlier. Higher R&D and G&A expenses, linked to preparing the SIL204 Phase 2/3 trial, were partly offset by financial income from revaluation of financial instruments.
What were Silexion Therapeutics’ (SLXN) year-to-date 2026 results?
For the six months ended June 30, 2026, Silexion posted a net loss of $6.3 million, versus $4.2 million in 2025. R&D expenses rose to $3.6 million and G&A to $2.8 million, reflecting clinical ramp-up and public-company costs.
What is the cash position and equity of Silexion Therapeutics (SLXN)?
As of June 30, 2026, Silexion held $2.229 million in cash and cash equivalents and total assets of $4.246 million. Shareholders’ equity declined to $44 thousand, down from $2.603 million at December 31, 2025.
What progress has Silexion Therapeutics (SLXN) made with SIL204?
Silexion advanced SIL204 into an active Phase 2/3 trial in locally advanced pancreatic cancer, with approvals in Israel and Germany. The first clinical site at Tel Aviv Sourasky Medical Center was initiated on July 29, 2026, enabling patient screening to begin.
What recent financing has Silexion Therapeutics (SLXN) completed?
On August 13, 2026, Silexion closed a registered public offering with aggregate gross proceeds of approximately $2.5 million and net proceeds of about $2.1 million, complementing prior warrant inducements, ATM share sales, and related party promissory note conversions.
Does Silexion Therapeutics (SLXN) face going-concern risks?
Yes. The company highlighted substantial doubt about its ability to continue as a going concern in Note 1(g) to its June 30, 2026 financial statements, reflecting limited equity, losses, and future capital requirements.
How have Silexion Therapeutics’ (SLXN) R&D expenses changed?
R&D expenses rose to $2.2 million in Q2 2026 from $1.0 million a year earlier, a 120.0% increase. For the six months, R&D reached $3.6 million, up 125.0%, mainly due to Phase 2/3 trial preparations for SIL204.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
|
of incorporation)
|
|
|
Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
+972 -3-756-4999
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 14, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the second
quarter and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.
The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor
will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may be expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
99.1
|
|
Press Release, dated August 14, 2026, titled “Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update”
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
|
SILEXION THERAPEUTICS CORP
|
|
|
|
|
|
|
Date: August 14, 2026
|
By:
|
/s/ Ilan Hadar
|
|
|
Name:
|
Ilan Hadar
|
|
|
Title:
|
Chief Executive Officer
|
Exhibit 99.1
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in
locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026
following clinical trial authorizations from regulators in both Israel and Germany
Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a
coordinated immune-sensitization signature across three key immune pathways and four KRAS
mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies
Advanced operational and financial readiness for the Phase 2/3 program, including initiation of GMP
clinical supply manufacturing with a leading global CDMO
Grand Cayman, Cayman Islands, August 14, 2026 — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced financial results for the
three-month and six-month periods ended June 30, 2026, and provided a business update.
Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “The second quarter of 2026 and the period since that time have
represented the most consequential stretch in Silexion’s history, as we have transitioned SIL204 from a preclinical and regulatory-preparation asset into an active Phase 2/3 clinical program. With clinical trial authorization from Germany’s BfArM
added to the previously received approval from the Israeli Ministry of Health, and the successful initiation of our first clinical site at Tel Aviv Sourasky Medical Center at the end of July, our focus has shifted entirely to clinical execution. In
parallel, we continued to expand the scientific profile of SIL204 with new immuno-oncology data supporting a coordinated immune-sensitization signature across four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1
checkpoint inhibitors. We believe this combination of clinical, regulatory, manufacturing, and translational progress positions Silexion at the beginning of what should be a defining stretch for the Company.”
Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the second quarter and subsequent to quarter end, we
successfully executed a series of financing transactions. Most recently, we closed a public offering with gross proceeds of approximately $2.5 million. All of those transactions were designed to strengthen our balance sheet and support the transition
of SIL204 into its recently initiated Phase 2/3 Clinical Trial, bringing new hope to the patients who need it most, alongside supporting compliance with applicable Nasdaq continued listing requirements.”
Recent Milestones & Business Highlights
Phase 2/3 Clinical Program Advanced Across
Israel and Germany, and Successfully Initiated at Tel Aviv Sourasky Medical Center: During the second quarter and subsequent to quarter end, Silexion advanced SIL204 into active Phase 2/3 clinical evaluation in locally advanced pancreatic
cancer. In April 2026, the Company submitted its Clinical Trial Application to Germany’s Federal Institute for Drugs and Medical Devices (BfArM) through the EU Clinical Trials Information System, with Germany serving as Reference Member State for the
European program. In June 2026, the Company received CTA approval from BfArM, accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, adding Germany to the previously received approval from the Israeli
Ministry of Health. In May 2026, the Company initiated GMP clinical supply manufacturing of SIL204 with a leading global contract development and manufacturing organization (CDMO), further supporting the operational readiness of the program. On July
29, 2026, subsequent to quarter end, Silexion successfully initiated the Phase 2/3 clinical trial at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel’s largest and most prominent academic medical centers, clearing the site to
commence patient screening, with first patient dosing anticipated to follow. Additional Israeli and German trial sites are progressing through activation and are expected to join the program in the coming months.
Expanded Immuno-Oncology Profile for SIL204
- Coordinated Immune-Sensitization Signature Across Three Pathways and Four KRAS Mutations: During and subsequent to the second quarter, Silexion reported preclinical findings that extended SIL204’s therapeutic profile beyond direct
anti-tumor activity into immune sensitization. In May 2026, the Company reported statistically significant upregulation of MHC-I following SIL204 treatment in human KRAS-mutant pancreatic and non-small cell lung cancer cells, supporting potential
future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®). In August 2026, the Company reported additional statistically significant upregulation of FAS (CD95), the immune “death receptor,” and downregulation of HLA-G, an
established immune checkpoint, across three distinct KRAS mutations in pancreatic and non-small cell lung cancer cell lines. Taken together, these findings support a coordinated immune-sensitization signature across three key immune pathways —
increased antigen presentation, restored susceptibility to immune-mediated apoptosis, and reduced immune checkpoint activity — observed across four KRAS mutations (G12D, G12V, G12C, and G12R), reinforcing the scientific rationale for combining SIL204
with anti-PD-(L)1 checkpoint inhibitor therapies.
Capital-Structure Actions to Support
Clinical Execution and Continued Nasdaq Listing: During the second quarter and subsequent to quarter end, Silexion executed a series of financing transactions in support of the Phase 2/3 clinical program and support compliance with
applicable Nasdaq continued listing requirements, including a May 2026 warrant exercise inducement transaction, ongoing sales of ordinary shares under the Company’s at-the-market facility, further partial conversions of principal under its related
party promissory note, shareholder-approved successive increases in authorized share capital, and a 1-for-10 reverse share split effected on May 28, 2026. Most recently, on August 13, 2026, the Company closed a registered public offering with
aggregate gross proceeds of approximately $2.5 million and net proceeds of approximately $2.1 million.
Financial Results for the Three Months Ended June 30, 2026
Research and development (“R&D”) expenses for the three months ended June 30, 2026, were approximately $2.2 million, compared to
approximately $1.0 million for the three months ended June 30, 2025, an increase of 120.0%. The increase resulted mainly from an increase in subcontractors’ and
consultants’ expenses related to the operational ramp-up and preparations, required to support the initiation of our Phase 2/3 human clinical trial, which was initiated in July 2026.
General and administrative (“G&A”) expenses for the three months ended June 30, 2026, were approximately $1.5 million, compared to
approximately $1.3 million for the three months ended June 30, 2025, an increase of 15.4%. The increase resulted mainly from an increase in professional services
costs, primarily related to consultants and other expenses associated with the costs of operating as a public company.
Financial expenses (income), net for the three months ended June 30, 2026, were approximately $(0.1) million of financial income, net,
compared to approximately $0.2 million of financial expenses, net, for the three months ended June 30, 2025. The change was mainly due to the revaluation of the related party promissory note.
Net loss for the three months ended June 30, 2026, was approximately $3.6 million, compared to approximately $2.5 million for the three
months ended June 30, 2025, an increase of 44.0%. The increase was mainly due to higher research and development expenses related to preparations for the human
clinical trial initiated in July 2026, and higher general and administrative expenses, partly offset by a decrease in financial expenses, net, due to the revaluation of financial instruments.
Financial Results for the Six Months Ended June 30, 2026
R&D expenses for the six months ended June 30, 2026, were approximately $3.6 million, compared to approximately $1.6 million for the
six months ended June 30, 2025, an increase of 125.0%. The increase was primarily attributable to higher subcontractors’ and consultants’ expenses related to the
operational ramp-up and preparations, required to support the initiation of the Company’s Phase 2/3 human clinical trial, which was initiated in July 2026.
G&A expenses for the six months ended June 30, 2026, were approximately $2.8 million, compared to approximately $2.3 million for the
six months ended June 30, 2025, an increase of 21.7%. The increase resulted mainly from an increase in professional services costs, primarily related to legal,
consultants, and other expenses associated with the costs of operating as a public company.
Financial expenses (income), net for the six months ended June 30, 2026, were approximately $(0.1) million of financial income, compared to
approximately $0.3 million of financial expenses for the six months ended June 30, 2025. The decrease was mainly due to the revaluation of the related party promissory note.
Net loss for the six months ended June 30, 2026, was approximately $6.3 million, compared to approximately $4.2 million for the six months
ended June 30, 2025, an increase of 50.0%. The increase was mainly due to higher research and development expenses (mainly related to preparations for the human
clinical trial, initiated in July 2026) and higher general and administrative expenses, partly offset by a decrease in financial expenses, net, due to the revaluation of financial instruments.
Balance Sheet
| • |
As of June 30, 2026, the Company had cash and cash equivalents of approximately $2.2 million, compared to approximately $6.0 million as of December 31, 2025.
|
| • |
During the second quarter and subsequent to quarter end, the Company strengthened its capital position through a series of financing transactions, most recently the
closing on August 13, 2026, of a public offering yielding aggregate gross proceeds of approximately $2.5 million. As a result of these transactions and those detailed in the Company’s Quarterly Report on Form 10-Q, the Company estimates that
its shareholders’ equity, as of June 30, 2026 (as adjusted to reflect the foregoing transactions to date), is currently approximately $3.2 million, which
exceeds the Nasdaq Capital Market's $2.5 million minimum shareholders' equity requirement for continued listing. Accordingly, the Company believes that it has restored compliance with the applicable shareolders' equity requirement.
|
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation in Israel and the European Union in locally advanced pancreatic cancer. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation in Israel and the European Union in locally advanced pancreatic cancer. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including, for example, statements regarding the development of SIL204; the timing, initiation, design, and conduct of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (including the timing of site activation, patient screening, and first patient dosing at Tel Aviv Sourasky Medical Center and at additional Israeli and German trial sites), and any other current or planned clinical studies; the timing, content, outcome, and review of regulatory submissions and interactions with regulatory authorities in Israel, Germany, the European Union, and other jurisdictions; the timing and results of additional preclinical, translational, immuno-oncology, toxicology, manufacturing, and operational readiness activities, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, immune-sensitization profile, and clinical utility of SIL204 and any future product candidates across multiple KRAS-driven cancer types; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through public and private equity offerings, its at-the-market facility, warrant exercise inducement transactions, and other financing arrangements; the outcome of, and the Company’s response to, the legal proceedings described in Item 1 of Part II of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026; and Silexion’s belief that it has restored compliance with Nasdaq continued listing requirements (including estimates of the Company’s shareholders’ equity underlying such compliance), are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204; (ii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iii) the impact of the regulatory environment and compliance complexities; (iv) whether Silexion is able to develop future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vi) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(g) to the Company’s unaudited condensed consolidated financial statements for the three-month and six-month periods ended June 30, 2026; (vii) whether Silexion succeeds at maintaining its Nasdaq listing, including based on compliance with the shareholders’ equity requirement and any potential increase to the market value of listed securities requirement; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the SEC on or about August 14, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including, for example, statements regarding the development of SIL204; the timing, initiation, design, and conduct of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (including the timing of site activation, patient screening, and first patient dosing at Tel Aviv Sourasky Medical Center and at additional Israeli and German trial sites), and any other current or planned clinical studies; the timing, content, outcome, and review of regulatory submissions and interactions with regulatory authorities in Israel, Germany, the European Union, and other jurisdictions; the timing and results of additional preclinical, translational, immuno-oncology, toxicology, manufacturing, and operational readiness activities, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, immune-sensitization profile, and clinical utility of SIL204 and any future product candidates across multiple KRAS-driven cancer types; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through public and private equity offerings, its at-the-market facility, warrant exercise inducement transactions, and other financing arrangements; the outcome of, and the Company’s response to, the legal proceedings described in Item 1 of Part II of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026; and Silexion’s belief that it has restored compliance with Nasdaq continued listing requirements (including estimates of the Company’s shareholders’ equity underlying such compliance), are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204; (ii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iii) the impact of the regulatory environment and compliance complexities; (iv) whether Silexion is able to develop future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vi) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(g) to the Company’s unaudited condensed consolidated financial statements for the three-month and six-month periods ended June 30, 2026; (vii) whether Silexion succeeds at maintaining its Nasdaq listing, including based on compliance with the shareholders’ equity requirement and any potential increase to the market value of listed securities requirement; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the SEC on or about August 14, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share data)
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share data)
|
June 30,
|
December 31,
|
|||||||
|
2026
|
2025
|
|||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
2,229
|
$
|
5,991
|
||||
|
Restricted cash
|
29
|
27
|
||||||
|
Prepaid expenses
|
1,372
|
570
|
||||||
|
Other current assets
|
111
|
49
|
||||||
|
TOTAL CURRENT ASSETS
|
3,741
|
6,637
|
||||||
|
NON-CURRENT ASSETS:
|
||||||||
|
Restricted cash
|
62
|
57
|
||||||
|
Long-term deposit and other non-current assets
|
75
|
84
|
||||||
|
Property and equipment, net
|
20
|
25
|
||||||
|
Operating lease right-of-use asset
|
348
|
412
|
||||||
|
TOTAL NON-CURRENT ASSETS
|
505
|
578
|
||||||
|
TOTAL ASSETS
|
$
|
4,246
|
$
|
7,215
|
||||
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(U.S. dollars in thousands, except share data)
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(U.S. dollars in thousands, except share data)
|
June 30,
|
December 31,
|
|||||||
|
2026
|
2025
|
|||||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
1,180
|
$
|
787
|
||||
|
Current maturities of operating lease liability
|
199
|
182
|
||||||
|
Employee related obligations
|
628
|
879
|
||||||
|
Other account payable
|
984
|
910
|
||||||
|
Private warrants to purchase ordinary shares (including $* due to related party as of June 30, 2026 and December 31, 2025)
|
*
|
*
|
||||||
|
Related Party Promissory Note
|
985
|
—
|
||||||
|
TOTAL CURRENT LIABILITIES
|
3,976
|
2,758
|
||||||
|
NON-CURRENT LIABILITIES:
|
||||||||
|
Long-term operating lease liability
|
226
|
286
|
||||||
|
Related Party Promissory Note
|
—
|
1,568
|
||||||
|
TOTAL NON-CURRENT LIABILITIES
|
$
|
226
|
$
|
1,854
|
||||
|
TOTAL LIABILITIES
|
$
|
4,202
|
$
|
4,612
|
||||
|
SHAREHOLDERS' EQUITY:
|
||||||||
|
Ordinary shares ($0.135 par value per share, 5,900,000 and 900,000 shares authorized as of June 30, 2026 and December 31, 2025,
respectively; 1,179,844 and 312,665 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively)
|
160
|
42
|
||||||
|
Additional paid-in capital
|
61,334
|
57,727
|
||||||
|
Accumulated deficit
|
(61,450
|
)
|
(55,166
|
)
|
||||
|
TOTAL SHAREHOLDERS' EQUITY
|
$
|
44
|
$
|
2,603
|
||||
|
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
|
$
|
4,246
|
$
|
7,215
|
||||
All share amounts reflect a 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d) to the
Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026
* Represents an amount less than $1.
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
|
Six months ended June 30,
|
Three months ended June 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
OPERATING EXPENSES:
|
||||||||||||||||
|
Research and development (including $176 and $0 from related party for the six-month periods ended June 30, 2026 and 2025,
respectively, and including $46 and $0 from related party for the three months period ended June 30, 2026 and 2025, respectively)
|
$
|
3,582
|
$
|
1,608
|
$
|
2,212
|
$
|
1,018
|
||||||||
|
General and administrative (including $282 and $58 from related party for the six-month periods ended June 30, 2026 and 2025,
respectively, and including $67 and $37 from related party for the three months period ended June 30, 2026 and 2025, respectively)
|
2,847
|
2,326
|
1,468
|
1,266
|
||||||||||||
|
TOTAL OPERATING EXPENSES
|
6,429
|
3,934
|
3,680
|
2,284
|
||||||||||||
|
OPERATING LOSS
|
6,429
|
3,934
|
3,680
|
2,284
|
||||||||||||
|
Financial expense (income), net (including $(169) and $229 from related party for the six months period ended June 30, 2026 and
2025, respectively, and including $(154) and $197 from related party for the three months period ended June 30, 2026 and 2025, respectively)
|
(145
|
)
|
301
|
(129
|
)
|
216
|
||||||||||
|
LOSS BEFORE INCOME TAX
|
$
|
6,284
|
$
|
4,235
|
$
|
3,551
|
$
|
2,500
|
||||||||
|
INCOME TAX
|
*
|
3
|
*
|
3
|
||||||||||||
|
NET LOSS
|
$
|
6,284
|
$
|
4,238
|
$
|
3,551
|
$
|
2,503
|
||||||||
|
LOSS PER SHARE, BASIC AND DILUTED
|
$
|
12.41
|
$
|
82.12
|
$
|
5.17
|
$
|
43.19
|
||||||||
|
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
506,202
|
51,613
|
**
|
687,353
|
57,952
|
**
|
||||||||||
* Represents an amount less than $1
** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive
basis) 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d) to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026